SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
22 Septembre 2022 - 2:30PM
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel therapies for a broad range of cancer
indications, today announced its upcoming poster presentation
related to its highly selective CDK9 inhibitor, GFH009, at the
Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO)
being held on September 28 through October 1, 2022, in Houston,
Texas and virtually.
The poster presentation characterizes the preclinical
pharmacokinetic (PK) profiles of two different formulations of
GFH009 maleate, pH 4.5 and pH 6.0.
Additional presentation details can be found below:
Title: “Pharmacokinetics and Bioequivalence of
Two Formulations of GFH009 Maleate Injection in Sprague Dawley
Rats”
Abstract #: AML-259
Date/Time: Wednesday, September 28, 2022 at
6:05 PM ET
Presenter: Dragan Cicic, MD, Senior Vice
President, Clinical Development, of SELLAS
About SELLAS Life Sciences Group, Inc. SELLAS
Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical
biopharmaceutical company focused on the development of novel
therapeutics for a broad range of cancer indications. SELLAS’ lead
product candidate, galinpepimut-S (GPS), is licensed from Memorial
Sloan Kettering Cancer Center and targets the WT1 protein, which is
present in an array of tumor types. GPS has potential as a
monotherapy or in combination with other therapies to address a
broad spectrum of hematologic malignancies and solid tumor
indications. The Company is also developing GFH009, a small
molecule, highly selective CDK9 inhibitor, which is licensed from
GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and
diagnostic uses in the world outside of Greater China.
For more information on SELLAS, please
visit www.sellaslifesciences.com.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts are “forward-looking statements,”
including those relating to future events. In some cases,
forward-looking statements can be identified by terminology such as
“plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,”
“project,” “believe,” “estimate,” “predict,” “potential,” “intend,”
or “continue” and other words or terms of similar meaning. These
statements include, without limitation, statements related to
preclinical data for GFH009, plans for further development of
GFH009, and the potential for GFH009 as a drug development
candidate. These forward-looking statements are based on current
plans, objectives, estimates, expectations and intentions, and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
and uncertainties associated with the COVID-19 pandemic and its
impact on the Company’s clinical plans and business strategy, risks
and uncertainties associated with oncology product development and
clinical success thereof, the uncertainty of regulatory approval,
and other risks and uncertainties affecting SELLAS and its
development programs as set forth under the caption “Risk Factors”
in SELLAS’ Annual Report on Form 10-K filed on March 31, 2022 and
in its other SEC filings. Other risks and uncertainties of which
SELLAS is not currently aware may also affect SELLAS’
forward-looking statements and may cause actual results and the
timing of events to differ materially from those anticipated. The
forward-looking statements herein are made only as of the date
hereof. SELLAS undertakes no obligation to update or supplement any
forward-looking statements to reflect actual results, new
information, future events, changes in its expectations or other
circumstances that exist after the date as of which the
forward-looking statements were made.
Investor Contact Allison Soss KCSA Strategic
Communications Email: SELLAS@kcsa.com Phone: 212.896.1267
Media Contacts Raquel Cona / Michaela Fawcett
KCSA Strategic Communications Email: SELLAS@kcsa.com Phone:
212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
SELLAS Life Sciences (NASDAQ:SLS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024